CD33 and acute myeloid leukemia: In 2000, under an accelerated approval process, the US FDA approved the first ADC, Mylotarg (gemtuzumab ozogamicin), which targets CD33 for the treatment of relapsed acute myeloid leukemia (AML) [23, 24].